← Eichor
Condition: Cutaneous Lupus Erythematosus Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Cutaneous Lupus Erythematosus

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

US Zamto-cel Autoimmune Diseases
Phase 1 · 1 location(s) · Miltenyi Biomedicine GmbH · NCT06708845A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
Phase 1 · 14 location(s) · CRISPR Therapeutics · NCT06925542Duke Lupus Registry
Phase N/A · 1 location(s) · Duke University · NCT00512694A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
Phase 3 · 13 location(s) · EMD Serono Research & Development Institute, Inc. · NCT07355218A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
Phase 3 · 13 location(s) · EMD Serono Research & Development Institute, Inc. · NCT07332481Maternal Autoimmune Disease Research Alliance (MADRA) Registry
Phase N/A · 1 location(s) · Duke University · NCT03276923Follow-up of the Systemic Lupus Erythematosus Cohort as Part of the Multidisciplinary Consultation at Brest CHRU
Phase N/A · 1 location(s) · University Hospital, Brest · NCT06551389Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease
Phase 1 · 2 location(s) · Seismic Therapeutic AU Pty Ltd · NCT07455578A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE/CLE Participants
Phase 1/Phase 2 · 7 location(s) · DualityBio Inc. · NCT06625671Cutaneous Lupus Registry
Phase N/A · 1 location(s) · University of Texas Southwestern Medical Center · NCT01266915Clinical Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of SOF-SKN in Healthy Participants
EARLY_Phase 1 · 1 location(s) · Noxopharm Limited · NCT07072611A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the
Phase 2 · 32 location(s) · Ventus Therapeutics U.S., Inc. · NCT07260877A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Dis
Phase 4 · 4 location(s) · Bristol-Myers Squibb · NCT06875960Study to Evaluate the Efficacy of Ruxolitinib 1.5% Cream in Adult Subjects with Discoid Lupus Erythematosus
Phase 2 · 2 location(s) · Innovaderm Research Inc. · NCT06261021Research Accelerated by You Lupus Registry
Phase N/A · 1 location(s) · Lupus Foundation of America · NCT06927219Prevalence and Clinical Severity of Cutaneous Lupus Erythematosus
Phase N/A · 2 location(s) · University of Pennsylvania · NCT01510067Evaluate the Efficacy and Safety of ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE) Double-blind Study
Phase 2 · 27 location(s) · Beijing InnoCare Pharma Tech Co., Ltd. · NCT07440537Systemic Lupus Erythematosus Within the Framework of the Multidisciplinary Consultation
NA · 1 location(s) · University Hospital, Brest · NCT04320680
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.